Taiwan biotech Great Novel Therapeutics launches Phase I trial for GNTbm-38 cancer therapy
Great Novel Therapeutics launches Phase I trial of GNTbm-38 after FDA IND approval. Discover what this epigenetic cancer immunotherapy could change.
Can IDE574 reshape breast and lung cancer treatment by targeting KAT6 and KAT7?
IDEAYA Biosciences files IND for IDE574, a KAT6/7 inhibitor for breast and lung cancer. Learn how this new class may change epigenetic treatment strategies.